Pedro ROMERO-AROCA

Prof. Pedro ROMERO-AROCA

Hospital Universitari Sant Joan de Reus
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Diabetologia
Verified
Journal Article
Open access
PDF file
NNNatalie Nanayakkara
Natalie Nanayakkara
ACAndrea Curtis
Andrea Curtis
SHstephane heritier
stephane heritier
AGAdelle Gadowski
Adelle Gadowski
MPMeda E. Pavkov
Meda E. Pavkov
SZSophia Zoungas
Sophia Zoungas
Aims/hypothesis: Few studies examine the association between age at diagnosis and subsequent complications from type 2 diabetes. This paper aims to summarise the risk of mortality, macrovascular complications and microvascular complications associated with age at diagnosis of type 2 diabetes. Methods: Data were sourced from MEDLINE and All EBM (Evidence Based Medicine) databases from inception to July 2018. Observational studies, investigating the effect of age at diabetes diagnosis on macrovascular and microvascular diabetes complications in adults with type 2 diabetes were selected according to pre-specified criteria. Two investigators independently extracted data and evaluated all studies. If data were not reported in a comparable format, data were obtained from authors, presented as minimally adjusted ORs (and 95% CIs) per 1 year increase in age at diabetes diagnosis, adjusted for current age for each outcome of interest. The study protocol was recorded with PROSPERO International Prospective Register of Systematic Reviews (CRD42016043593). Results: Data from 26 observational studies comprising 1,325,493 individuals from 30 countries were included. Random-effects meta-analyses with inverse variance weighting were used to obtain the pooled ORs. Age at diabetes diagnosis was inversely associated with risk of all-cause mortality and macrovascular and microvascular disease (all p < 0.001). Each 1 year increase in age at diabetes diagnosis was associated with a 4%, 3% and 5% decreased risk of all-cause mortality, macrovascular disease and microvascular disease, respectively, adjusted for current age. The effects were consistent for the individual components of the composite outcomes (all p < 0.001). Conclusions/interpretation: Younger, rather than older, age at diabetes diagnosis was associated with higher risk of mortality and vascular disease. Early and sustained interventions to delay type 2 diabetes onset and improve blood glucose levels and cardiovascular risk profiles of those already diagnosed are essential to reduce morbidity and mortality.

28 September 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
PRPedro ROMERO-AROCA
Pedro ROMERO-AROCA
BMBaget-Bernaldiz Marc
Baget-Bernaldiz Marc
APAlicia Pareja-Rios
Alicia Pareja-Rios
MLMaribel Lopez-Galvez
Maribel Lopez-Galvez
RNRaul Navarro-Gil
Raul Navarro-Gil
RVRaquel Verges
Raquel Verges
Diabetic macular edema (DME) can cause blindness in diabetic patients suffering from diabetic retinopathy (DR). DM parameters controls (glycemia, arterial tension, and lipids) are the gold standard for preventing DR and DME. Although the vascular endothelial growth factor (VEGF) is known to play a role in the development of DME, the pathological processes leading to the onset of this disease are highly complex and the exact sequence in which they occur is still not completely understood. Angiogenesis and inflammation have been shown to be involved in the pathogenesis of this disease. However, it still remains to be clarified whether angiogenesis following VEGF overexpression is a cause or a consequence of inflammation. This paper provides a review of the data currently available, focusing on VEGF, angiogenesis, and inflammation. Our analysis suggests that angiogenesis and inflammation act interdependently during the development of DME. Knowledge of DME etiology seems to be important in treatments with anti-VEGF or anti-inflammatory drugs. Current diagnostic techniques do not permit us to differentiate between both etiologies. In the future, diagnosing the physiopathology of each patient with DME will help us to select the most effective drug.

1 January 2011 in World Journal of Diabetes
Verified
Journal Article
Open access
PRPedro ROMERO-AROCA
Pedro ROMERO-AROCA
Diabetic macular edema (DME) is the leading cause of blindness in young adults in developed countries, affecting 12% of type 1 and 28% of type 2 diabetic patients. The gold standard DME treatment should be based on a good control of glycemia along with control of lipids and renal function. However, despite the systemic metabolic control values being essential for patients with diabetic retinopathy (DR), it has proven to be insufficient for DME if it appears. With these patients, additional measures are needed in order to avoid the subsequent loss of vision. While laser treatment of DME has been the only valid treatment so far, it has been inadequate in chronic cases. The introduction of new treatments, such as intravitreal corticosteroids or anti-VEGF drugs, have recently shown their safety and efficacy and together with laser photocoagulation are becoming the treatments of choice in the management of DME.

11 May 2010 in Ophthalmic Epidemiology
Verified
Journal Article
Closed access
PDF file
PRPedro ROMERO-AROCA
Pedro ROMERO-AROCA
SRSagarra-Alamo Ramon
Sagarra-Alamo Ramon
BMBaget-Bernaldiz Marc
Baget-Bernaldiz Marc
FJFernández-Ballart Juan
Fernández-Ballart Juan
MIMéndez-Marin Isabel
Méndez-Marin Isabel
Purpose: To determine the prevalence of microangiopathy, and its risk factors in a population-based study of diabetes mellitus patients in the north-eastern area of Spain. Methods: A population-based transversal study of 8,187 type 2 (83.37% of the diagnosed patients) and 488 type 1 (85.76% of the diagnosed patients) underwent a detailed medical history that included: diagnoses of diabetic retinopathy, macular edema, microalbuminuria or overt nephropathy. A study of its risk factors, and the relationship between diabetic retinopathy and renal lesion was performed. Results: In type 1 diabetes patients we observed a prevalence of 36.47% of diabetic retinopathy and 5.73% with macular edema; in type 2 diabetes patients the prevalence of diabetic retinopathy was 26.11% and 6.44% with macular edema. Microalbuminuria prevalence was 25.61% in type 1 and 17.78% in type 2 patients, and overt nephropathy prevalence was 8.60% in type 1 and 6.74% in type 2 diabetic patients. The risk factors for diabetic retinopathy were: diabetes duration, high glycosylated level, and arterial hypertension, and insulin treatment in type 2. The Total-cholesterol/High Density-cholesterol (TC/HDL) ratio and triglycerides were significant for diabetic macular edema (DME). Microalbuminuria and overt nephropathy were well correlated to diabetes duration, arterial hypertension and glycosylated haemoglobin. Conclusions: Prevalence and risk factors for microangiopathy are similar to other studies, and the important finding is that the TC/HDL ratio was significant for DME. Microalbuminuria is a risk factor for diabetic retinopathy in type 1 diabetes mellitus patients but not for type 2. Overt nephropathy is well correlated with diabetic retinopathy.

7 March 2017 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
PRPedro ROMERO-AROCA
Pedro ROMERO-AROCA
RNRaul Navarro-Gil
Raul Navarro-Gil
AVAida Valls-Mateu
Aida Valls-Mateu
RSRamon Sagarra-Alamo
Ramon Sagarra-Alamo
AMAntonio Moreno-Ribas
Antonio Moreno-Ribas
NSNuria Soler
Nuria Soler
Background/aims To determine the incidence of any diabetic retinopathy (any-DR), sight-threatening diabetic retinopathy (STDR) and diabetic macular oedema (DMO) and their risk factors in type 1 diabetes mellitus (T1DM) over a screening programme. Methods Nine-year follow-up, prospective population-based study of 366 patients with T1DM and 15 030 with T2DM. Epidemiological risk factors were as follows: current age, age at DM diagnosis, sex, type of DM, duration of DM, arterial hypertension, levels of glycosylated haemoglobin (HbA1c), triglycerides, cholesterol fractions, serum creatinine, estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR). Results Sum incidence of any-DR was 47.26% with annual incidence 15.16±2.19% in T1DM, and 26.49% with annual incidence 8.13% in T2DM. Sum incidence of STDR was 18.03% with annual incidence 5.77±1.21% in T1DM, and 7.59% with annual incidence 2.64±0.15% in T2DM. Sum incidence of DMO was 8.46% with annual incidence 2.68±038% in patients with T1DM and 6.36% with annual incidence 2.19±0.18% in T2DM. Cox's survival analysis showed that current age and age at diagnosis were risk factors at p<0.001, as high HbA1c levels at p<0.001, LDL cholesterol was significant at p<0.001, eGFR was significant at p<0.001 and UACR at p=0.017. Conclusions The incidence of any-DR and STDR was higher in patients with T1DM than those with T2DM. Also, the 47.26% sum incidence of any-DR in patients with T1DM was higher than in a previous study (35.9%), which can be linked to poor metabolic control of DM. Our results suggest that physicians should be encouraged to pay greater attention to treatment protocols for T1DM in patients.

1 April 2018 in Artificial Intelligence in Medicine
Verified
Journal Article
Closed access
ESEmran Saleh
Emran Saleh
JBJerzy Błaszczyński
Jerzy Błaszczyński
Antonio MorenoAntonio Moreno
Antonio Moreno
Aida VallsAida Valls
Aida Valls
PRPedro ROMERO-AROCA
Pedro ROMERO-AROCA
RSRoman Słowiński
Roman Słowiński